GFRAL (GDNF Receptor Alpha Like) encodes the receptor for Glial Cell Line-Derived Neurotrophic Factor (GDNF) family ligands. Located on chromosome 6p12.1, GFRAL is the founding member of the GDNF receptor family and serves as the exclusive high-affinity receptor for GDNF and related ligands.
GFRAL is a critical therapeutic target for neurodegenerative diseases, particularly Parkinson's disease, as it mediates the neuroprotective effects of GDNF on dopaminergic neurons.[1]
The protein encoded by GFRAL is GFRAL Protein.[2]
GFRAL is a cell surface receptor that belongs to the GDNF receptor family (GFRα). Unlike other GFRα family members (GFRα1-4) which can bind multiple ligands, GFRAL shows high specificity for GDNF. It functions as a co-receptor, requiring association with the RET tyrosine kinase to transduce signals into the cell.
The discovery of GFRAL as the GDNF receptor resolved decades of research into GDNF signaling mechanisms and opened new therapeutic avenues for neurodegenerative disease treatment.
| Property |
Value |
| Gene Symbol |
GFRAL |
| Full Name |
GDNF Receptor Alpha Like |
| Chromosome |
6p12.1 |
| NCBI Gene ID |
390538 |
| OMIM |
615866 |
| Ensembl ID |
ENSG00000173137 |
| UniProt ID |
Q6UXB5 |
¶ Protein Structure and Function
¶ Domain Architecture
GFRAL contains several structural features:
- N-terminal signal peptide: Targets protein to the secretory pathway
- ** extracellular domain**: Ligand binding
- Glycosylphosphatidylinositol (GPI) anchor: Membrane attachment
- C-terminal hydrophobic region: Membrane-spanning segment
GFRAL functions as part of a heteromeric receptor complex:
- GFRAL: High-affinity ligand binding
- RET: Tyrosine kinase transmembrane component
- GDNF: Ligand that bridges GFRAL and RET
Upon ligand binding:
- GDNF binds to GFRAL
- GFRAL recruits and activates RET
- RET autophosphorylates
- Multiple downstream pathways are activated:
- PI3K/Akt: Cell survival
- RAS/ERK: Neurite outgrowth
- PLCγ: Calcium signaling
GFRAL is expressed in specific neuronal populations:
- Substantia nigra pars compacta: Dopaminergic neurons
- Ventral tegmental area: Mesolimbic dopamine neurons
- Striatum: Medium spiny neurons
- Motor neurons: Spinal cord
- Enteric nervous system: Gut neurons
- Pancreas: Some endocrine cells
- Testis: Spermatogonia
GFRAL-mediated signaling promotes:
- Dopaminergic neuron survival: Critical for Parkinson's therapy
- Motor neuron maintenance: Relevant to ALS
- Neurite outgrowth: Promotes axonal regeneration
- Synapse formation: Supports synaptic connectivity
GDNF/GFRAL signaling affects:
- Dendritic arborization
- Synaptic plasticity
- Long-term potentiation
The GFRAL pathway supports:
- Axonal regeneration after injury
- Neuronal repair
- Functional recovery
GFRAL is a major therapeutic target in PD:
- Neuroprotection: GDNF preserves dopaminergic neurons
- Neurorestoration: Promotes function of surviving neurons
- Clinical trials: Multiple GDNF/GDNF mimetic trials
- GFRAL expressed in motor neurons
- GDNF delivery trials in ALS
- Potential for motor neuron protection
- GFRAL signaling promotes regeneration
- Potential for functional recovery
- Combined with rehabilitation
- Neuroprotective effects
- Supports post-stroke recovery
- Angiogenesis promotion
Multiple delivery strategies:
- Protein infusion: Direct GDNF delivery to brain
- Gene therapy: AAV-mediated GFRAL/RET expression
- Cell therapy: GDNF-producing cell transplants
- Small molecules: GFRAL agonists
- Monoclonal antibodies: Agonist antibodies
- Small molecule agonists: Non-peptide GFRAL activators
- Peptide mimetics: GDNF mimetics
Multiple clinical programs:
- Intraputaminal GDNF infusion: Shows promise in PD
- AAV2-GDNF: Gene therapy approaches
- Stem cell-derived neurons: Cell replacement therapy
Reduced GFRAL signaling contributes to:
- Progressive dopaminergic neuron loss
- Impaired neuronal resilience
- Accelerated disease progression
GDNF/GFRAL has anti-inflammatory effects:
- Reduces microglial activation
- Modulates cytokine production
- Protects against neuroinflammation
GFRAL signaling affects:
- Autophagy regulation
- Protein aggregate clearance
- ER stress responses
- Primary dopaminergic neuron cultures
- iPSC-derived neurons
- Motor neuron models
- Gfral knockout mice
- Gdnf knockout mice
- Parkinson's disease models
- GFRAL humanized mice
¶ Biomarkers and Diagnostics
- GFRAL expression levels
- Soluble GFRAL in CSF
- RET phosphorylation status
- GFRAL expression as predictor
- RET status for treatment response
- Genetic variants affecting response
The study of Gfral Gene Gdnf Receptor Alpha Like has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- GFRAL is the GDNF Receptor - Nature
- GFRAL Protein - UniProt
- GDNF Therapy in Parkinson's Disease - Brain
- GFRAL in Neurodegeneration - Trends in Pharmacological Sciences
- RET Receptor Signaling - Cold Spring Harbor Perspectives in Biology